INDICATIONS AND USAGE NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine, an intermediate-acting human insulin analog, and insulin aspart, a rapid-acting human insulin analog, indicated to improve glycemic control in patients with diabetes mellitus.
1 Inject Novolin 70/30 into the skin of your stomach area, upper arms, buttocks or upper legs. 2 Change (rotate) your injection site within the chosen area (for example, stomach or upper arm) with each dose. 3 If you take too much Novolin 70/30, your blood sugar may fall low (hypoglycemia).
Do not mix Novolin 70/30 with any insulins. Inject Novolin 70/30 into the skin of your stomach area, upper arms, buttocks or upper legs. Novolin 70/30 may affect your blood sugar levels sooner if you inject it into the skin of your stomach area.
These Novolin 70/30 PenFill 3 mL cartridges are designed for use with Novo Nordisk ® 3 mL PenFill cartridge compatible insulin delivery devices, with or without the addition of a NovoPen ® 3 PenMate ®, and NovoFine ® disposable needles.
Administer NOVOLIN® 70/30 by subcutaneous injection in the abdominal wall, thigh, upper arm, or buttocks. Rotate the injection site within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.
It is a mixture of 70% intermediate-acting insulin (isophane) and 30% short-acting insulin (regular). It starts to work as quickly as regular insulin but lasts longer. This insulin product works by helping blood sugar (glucose) get into cells so your body can use it for energy.
Novolin 70/30 is the same as Humulin 70:30. Novolin and Humulin are brands of insulin made by different companies. Novolin is made by Novo Nordisk and Humulin is made by Eli Lilly and Company.
Novolin 70/30 is a man-made insulin (recombinant DNA origin) which is a mixture of 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection that is structurally identical to the insulin produced by the human pancreas that is used control high blood sugar in patients with diabetes mellitus.
Administer Novolin 70/30 by subcutaneous injection in the abdominal wall, thigh, upper arm, or buttocks. Rotate the injection site within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.
Official answer. The main difference between these two insulins is that Novolog 70/30 - contains an intermediate acting and a very fast acting insulin, whereas Novolin 70/30 contains an intermediate acting insulin and a short acting insulin.
Most patients require 0.5 to 1.2 units/kg/day. Average initial dose: Type 1 DM, 0.5 to 0.6 units/kg/day; Type 2 DM, 0.2 to 0.6 units/kg/day. Initially, give about 2/3 daily dose before breakfast and 1/3 before evening meal. Administer 30 to 60 minutes before the start of the meal.
Novolin 70/30 releases a hormone called insulin into the body to lower blood sugar levels in the blood. It's a short-acting insulin that starts to work within 30 minutes after injection and keeps working for up to 24 hours.
Both Humulin R and Humulin N are used in adults and children with either type 1 or type 2 diabetes. And both medications contain the active drug insulin human. These medications help manage blood sugar levels. Humulin R is a short-acting insulin, while Humulin N is an intermediate-acting insulin.
U-100 insulins, including Humulin 70/30, contain 100 units/mL. With the Humulin 70/30 vial, it is important to use a syringe that is marked for U-100 insulins.
There was no difference in incidence of hypoglycaemia. Conclusions: Switching from human insulin mix 30:70 to analog insulin mix 50:50 results in better post main meal control in Ramadan, without affecting HbA1c, or increasing the incidence of hypoglycaemia.
NovoLog® Mix 70/30 can be dosed within 15 minutes before or after starting a meal in adult patients with type 2 diabetes, compared with 30 minutes before a meal required by human premixed insulin.
Novolin® 70/3010 mL Vial70% NPH, Human Insulin Isophane Suspension and30% Regular, Human Insulin Injection(recombinant DNA origin)NDC 0169-1837-11L...
Novolin® 70/30 PenFill®3 mL70% NPH, Human Insulin Isophane Suspension and30% Regular, Human Insulin Injection(recombinant DNA origin)NDC 0169-3477-...
Novolin® 70/30 InnoLet®3 mL70% NPH, Human Insulin Isophane Suspension and30% Regular, Human Insulin Injection(recombinant DNA origin)NDC 0169-2317-...
Novolin 70/30 is a mixture of 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin). The concentration of this product is 100 units of insulin per milliliter. It is a cloudy or milky suspension of human insulin with protamine and zinc.
Inject Novolin 70/30 into the skin of your stomach area, upper arms, buttocks or upper legs. Novolin 70/30 may affect your blood sugar levels sooner if you inject it into the skin of your stomach area. Never inject Novolin 70/30 into a vein or into a muscle.
a. If you need to perform more than 6 air shots before the first use of Novolin ® 70/30 InnoLet ® to get a drop of insulin at the needle tip, do not use.
Take Novolin 70/30 exactly as prescribed. Novolin 70/30 is an intermediate-acting insulin. The effects of Novolin 70/30 start working ½ hour after injection.
These Novolin 70/30 PenFill 3 mL cartridges are designed for use with Novo Nordisk ® 3 mL PenFill cartridge compatible insulin delivery devices, with or without the addition of a NovoPen ® 3 PenMate ®, and NovoFine ® disposable needles.
Novolin ® 70/30 InnoLet ® is a disposable dial-a-dose insulin delivery system able to deliver 1-50 units in increments of 1 unit. Novolin ® 70/30 InnoLet ® is designed and recommended for use with NovoFine ® single-use needles. Novolin ® 70/30 InnoLet ® is not recommended for the blind or severely visually impaired patients without the assistance of a sighted individual trained in the proper use of this product.
If you forget to take your dose of Novolin 70/30, your blood sugar may go too high (hyperglycemia). If high blood sugar (hyperglycemia) is not treated it can lead to diabetic ketoacidosis, which can lead to serious problems, like loss of consciousness (passing out), coma or even death.
12.1 Mechanism of Action - The primary activity of insulin, including NOVOLOG MIX 70/30 is the regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating ... 12.1 Mechanism of Action. The primary activity of insulin, including NOVOLOG MIX 70/30 is the regulation of glucose metabolism.
NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine, an intermediate-acting human insulin analog, and insulin aspart, a rapid-acting human insulin analog, indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use:
The 30% insulin aspart in the soluble component of NOVOLOG MIX 70 /30 is absorbed rapidly from the subcutaneous layer. The remaining 70% is in crystalline form as insulin aspart protamine which has a prolonged absorption profile after subcutaneous injection.
If not, change the needle and repeat the procedure no more than 6 times. If you do not see a drop of insulin after 6 times, do not use the NovoLog Mix 70/30 FlexPen and contact Novo Nordisk at 1-800-727-6500. A small air bubble may remain at the needle tip, but it will not be injected.
The primary activity of insulin, including NOVOLOG MIX 70/30 is the regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Limitations of Use: •. NOVOLOG MIX 70/30 is not recommended for the treatment of diabetic ketoacidosis.
There are no data on the presence of NOVOLOG MIX 70/30 in human milk, the effects on the breastfed infant, or the effect on milk production. One small published study reported that exogenous insulin, including insulin aspart, was present in human milk.
Read the Patient Information Leaflet provided by your pharmacist before you start using combination isophane/regular insulin and each time you get a refill. If you have any questions, ask your doctor, diabetes educator, or pharmacist.
This survey is being conducted by the WebMD marketing sciences department.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
Store the Novolin 70/30 FlexPen you are currently using out of the refrigerator at room temperature below 86°F (30°C) for up to 28 days.
The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulin preparations, the time course of glucose lowering effect of NOVOLIN 70/30 may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature . Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication [see Drug Interactions (7)]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.6, 8.7)].
Inform patients that hypoglycemia is the most common adverse reaction with insulin. Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia , especially at initiation of NOVOLIN 70/30 therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia [see Warnings and Precautions (5.3)].
The time course of insulin action (i.e., glucose lowering) may vary considerably in different individuals or within the same individual. NOVOLIN 70/30 is an intermediate-acting insulin with up to
Do not expose NOVOLIN 70/30 vials and NOVOLIN 70/30 FlexPen to excessive heat or light. Do not freeze. Do not use after the expiration date.
The effect of age on the pharmacokinetics and pharmacodynamics of NOVOLIN 70/30 has not been studied. Elderly patients using insulin, including NOVOLIN 70/30, may be at increased risk of hypoglycemia due to co-morbid disease [see Warnings and Precautions (5.3)].
There are no adverse reactions reported in the breastfed infants in the literature. There are no data on the effects of exogenous human insulin products, including NOVOLIN 70/30, on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NOVOLIN 70/30, and any potential adverse effects on the breastfed infant from NOVOLIN 70/30, or from the underlying maternal condition.
Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including Novolog Mix 70/30. The rates of reported hypoglycemia depend on the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. For these reasons, comparing rates of hypoglycemia in clinical trials for Novolog Mix 70/30 with the incidence of hypoglycemia for other products may be misleading and also, may not be representative of hypoglycemia rates that will occur in clinical practice.
The primary activity of insulin, including Novolog Mix 70/30 is the regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
If not, change the needle and repeat the procedure no more than 6 times. If you do not see a drop of insulin after 6 times, do not use the Novolog Mix 70/30 FlexPen and contact Novo Nordisk at 1-800-727-6500. A small air bubble may remain at the needle tip, but it will not be injected.
The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of Novolog Mix 70/30 may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature [see Clinical Pharmacology (12.2)]. Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication [see Drug Interactions (7)]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.6, 8.7)].
Inform patients that hypoglycemia is the most common adverse reaction with insulin. Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia , especially at initiation of Novolog Mix 70/30 therapy.
These reactions usually resolve in a few days to a few weeks, but in some occasions, have required discontinuation of Novolog Mix 70/30. Severe cases of generalized allergy (anaphylaxis) have been reported.
Hypoglycemia is the most common adverse effect of all insulins, including Novolog Mix 70/30. Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).